SynthesisFrontiers in oncology2022

Risk of Adverse Events in Cancer Patients Receiving Nivolumab With Ipilimumab: A Meta-Analysis.

Xin Zhao et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.